US stock · Healthcare sector · Drug Manufacturers—Specialty & Generic
Company Logo

Catalent, Inc.

CTLTNYSE

67.00

USD
+10.95
(+19.54%)
Pre Market
27.80P/E
18Forward P/E
1.26P/E to S&P500
12.058BMarket CAP
- -Div Yield
Upcoming Earnings
7 Feb
Shares Short
1/13/23
5.98M
Short % of Float
3.72%
Short % of Shares Outs.
3.32%
% Held by Insiders
0.36%
% Held by Institutions
104.48%
Beta
1.22
PEG Ratio
2.06
52w. high/low
115.33/40.69
Avg. Daily Volume
2.96M
Return %
Stock
S&P 500
1 year
(35.73)
(8.58)
3 years
15.32
23.39
5 years
- -
- -
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
46.43
29.23
58.38
29.29
120.48
31.04
142.64
97.86
128.26
40.69
70.03
44.49
Currency: USD
- -
- -
- -
- -
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
- -
- -
- -
- -
13.06
14.45
15.35
15.58
15.27
14.81
16.60
18.78
17.46
20.66
23.80
27.43
26.99
Earnings per share
- -
- -
- -
- -
(0.46)
(0.21)
(0.40)
0.14
1.77
0.89
0.88
0.64
0.92
1.47
3.48
2.95
2.35
FCF per share
- -
- -
- -
- -
0.11
(0.14)
0.13
0.48
0.26
0.13
1.28
1.51
0.21
(0.17)
(1.51)
(1.26)
(2.63)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.24
0.13
0.02
- -
CAPEX per share
- -
- -
- -
- -
0.74
0.89
1.04
1.04
1.18
1.12
1.12
1.35
1.51
3.11
4.08
3.75
3.66
Book Value per sh.
- -
- -
- -
- -
- -
(2.99)
(3.50)
(3.16)
5.29
5.10
5.79
8.28
11.66
23.40
25.44
27.24
26.03
Comm.Shares outs.
- -
- -
- -
- -
117
117
117
117
120
125
125
131
144
150
168
176
179
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
63.8
51.5
51.9
34.0
30.6
27.8
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.6
2.1
1.4
1.1
1.4
1.3
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.3%
0.1%
0.0%
- -
Revenue (m)
- -
- -
- -
- -
1,532
1,695
1,800
1,828
1,831
1,848
2,075
2,463
2,518
3,094
3,998
4,828
4,825
Operating margin
- -
- -
- -
- -
12.1%
11.7%
11.4%
13.2%
14.2%
11.8%
11.3%
11.0%
10.9%
12.7%
20.7%
15.7%
13.6%
Depreciation (m)
- -
- -
- -
- -
116
130
152
143
141
141
147
190
229
254
289
378
396
Net profit (m)
- -
- -
- -
- -
(54)
(24)
(47)
16
212
112
110
84
132
221
585
519
426
Income tax rate
- -
- -
- -
- -
(438.9)%
2.7%
(100.8)%
73.4%
(86.8)%
23.3%
19.0%
45.0%
14.3%
15.2%
18.2%
14.2%
36.6%
Net profit margin
- -
- -
- -
- -
(3.5)%
(1.4)%
(2.6)%
0.9%
11.6%
6.0%
5.3%
3.4%
5.2%
7.1%
14.6%
10.7%
8.3%
Working capital (m)
- -
- -
- -
- -
- -
265
268
235
339
399
591
663
725
1,400
1,722
1,844
1,755
Long-term debt (m)
- -
- -
- -
- -
- -
2,640
2,657
2,685
1,864
1,833
2,055
2,649
2,883
2,945
3,166
4,171
4,098
Equity (m)
- -
- -
- -
- -
- -
(351)
(411)
(371)
634
636
724
1,087
1,682
3,505
4,274
4,795
4,700
ROIC
- -
- -
- -
- -
- -
5.7%
13.7%
2.3%
14.9%
6.6%
6.1%
3.7%
4.1%
4.8%
8.5%
6.6%
4.5%
Return on capital
- -
- -
- -
- -
- -
5.1%
5.9%
7.4%
7.0%
7.6%
6.5%
5.8%
4.3%
5.0%
9.1%
6.9%
6.4%
Return on equity
- -
- -
- -
- -
- -
7.0%
11.4%
(4.4)%
33.5%
17.5%
15.2%
7.7%
7.8%
6.3%
13.7%
10.8%
9.1%
Plowback ratio
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
83.6%
96.2%
99.2%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
(0.4)%
(3,047.1)%
- -
- -
(140.3)%
(1,505.1)%
3,962.0%
23.7%
(1.8)%
- -
Capital Structure
1 Nov · 2022 | Q1
All numbers in millions
Total liabilities
$ 5,505
Total assets
$ 10,205
Long-term debt
$ 4,098
Cash and equiv.
$ 281
Goodwill
$ 2,929
Retained earnings
$ 538
Common stock
180
Enterprise Value
$ 15,875
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
953
967
538
Receivables
919
1,243
1,497
Inventory
347
593
724
Other
74
58
(347)
Current assets
2,293
2,918
2,916
Acc. Payable
321
385
421
Debt due
73
91
45
Other
499
720
606
Current liabilities
893
1,196
1,072
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
20.76%
18.77%
12.08%
Cash flow
(12.65)%
152.08%
191.48%
Earnings
(11.28)%
69.72%
142.36%
Dividends
(81.82)%
- -
- -
Book value
12.19%
49.33%
(2.09)%
Insider Trading
Type
Shares
Date
Hopson Ricky
Sale
643
01/23/23
Boerman Manja
Sale
780
12/05/22
Grippo Michael J
Sale
2,451
10/31/22
Zippelius Peter
Award
4,149
10/27/22
Morel Donald E Jr
Award
4,149
10/27/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
846
911
1,053
1,188
3,998
2022
1,025
1,217
1,273
1,313
4,828
2023
1,022
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.49
0.53
1.38
1.09
3.48
2022
0.53
0.55
0.80
1.07
2.95
2023
- -
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.05
0.03
0.03
0.03
0.13
2022
0.02
- -
- -
- -
0.02
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
CEO:
Mr. John Chiminski
Full-time employees:
19,000
City:
Somerset
Address:
14 Schoolhouse Rd
IPO:
Jul 31, 2014
Website:
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Recent News